The focus of current news stories is on the development of new drugs that *might* reduce mortality in Ebola. (One of these, ZMapp, has recently been abandoned amid rumours that it costs $100,000 for a course of treatment.) We should not forget that most deaths could be avoided through *existing* supportive measures, in particular fluid replacement. It is no accident that death rates from those treated in West Africa were as high as 80%, while those treated in the USA and other high-income countries have been close to zero. The priority is to empower frontline health workers in West Africa to provide intensive supportive care.